Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$5.54 USD
+0.86 (18.38%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $5.52 -0.02 (-0.36%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Moleculin Biotech, Inc. (MBRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$43.32 | $44.98 | $40.00 | 681.95% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Moleculin Biotech, Inc. comes to $109.94. The forecasts range from a low of $44.98 to a high of $239.88. The average price target represents an increase of 2% from the last closing price of $4.68.
Analyst Price Targets (3 )
Broker Rating
Moleculin Biotech, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/26/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
12/14/2023 | H.C. Wainwright & Co. | Vernon Bernardino | Not Available | Strong Buy |
8/11/2023 | Roth Capital Partners | Jonathan Aschoff | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 3 |
Average Target Price | $109.94 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -3.00 |